Cargando…

Continuous Glucose Monitoring System Based on Percutaneous Microneedle Array

A continuous blood glucose monitoring system (CGMS) which include a microneedle-array blood glucose sensor, a circuit module, and a transmission module placed in a wearable device is developed in this research. When in use, the wearable device is attached to the human body with the microneedle array...

Descripción completa

Detalles Bibliográficos
Autores principales: Chien, Ming-Nan, Chen, Yu-Jen, Bai, Chin-Han, Huang, Jung-Tung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949222/
https://www.ncbi.nlm.nih.gov/pubmed/35334773
http://dx.doi.org/10.3390/mi13030478
_version_ 1784674843388542976
author Chien, Ming-Nan
Chen, Yu-Jen
Bai, Chin-Han
Huang, Jung-Tung
author_facet Chien, Ming-Nan
Chen, Yu-Jen
Bai, Chin-Han
Huang, Jung-Tung
author_sort Chien, Ming-Nan
collection PubMed
description A continuous blood glucose monitoring system (CGMS) which include a microneedle-array blood glucose sensor, a circuit module, and a transmission module placed in a wearable device is developed in this research. When in use, the wearable device is attached to the human body with the microneedle array inserted under the skin for continuous blood glucose sensing, and the measured signals are transmitted wirelessly to a mobile phone or computer for analysis. The purpose of this study is to replace the conventionally used method of puncture for blood collection and test strips are used to measure the blood glucose signals. The microneedle sensor of this CGMS uses a 1 mm length needle in a 3 mm × 3 mm microneedle array for percutaneous minimally invasive blood glucose measurement. This size of microneedle does not cause bleeding damage to the body when used. The microneedle sensor is placed under the skin and their solutions are discussed. The blood glucose sensor measured the in vitro simulant fluid with a glucose concentration range of 50~400 mg/dL. In addition, a micro-transfer method is developed to accurately deposit the enzyme onto the tip of the microneedle, after which cyclic voltammetry (CV) is used to measure the glucose simulation solution to verify whether the difference in the amount of enzyme on each microneedle is less than 10%. Finally, various experiments and analyses are carried out to reduce the size of the device, test effective durability (approximately 7 days), and the feasibility of minimally invasive CGMS is evaluated by tests on two persons.
format Online
Article
Text
id pubmed-8949222
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89492222022-03-26 Continuous Glucose Monitoring System Based on Percutaneous Microneedle Array Chien, Ming-Nan Chen, Yu-Jen Bai, Chin-Han Huang, Jung-Tung Micromachines (Basel) Article A continuous blood glucose monitoring system (CGMS) which include a microneedle-array blood glucose sensor, a circuit module, and a transmission module placed in a wearable device is developed in this research. When in use, the wearable device is attached to the human body with the microneedle array inserted under the skin for continuous blood glucose sensing, and the measured signals are transmitted wirelessly to a mobile phone or computer for analysis. The purpose of this study is to replace the conventionally used method of puncture for blood collection and test strips are used to measure the blood glucose signals. The microneedle sensor of this CGMS uses a 1 mm length needle in a 3 mm × 3 mm microneedle array for percutaneous minimally invasive blood glucose measurement. This size of microneedle does not cause bleeding damage to the body when used. The microneedle sensor is placed under the skin and their solutions are discussed. The blood glucose sensor measured the in vitro simulant fluid with a glucose concentration range of 50~400 mg/dL. In addition, a micro-transfer method is developed to accurately deposit the enzyme onto the tip of the microneedle, after which cyclic voltammetry (CV) is used to measure the glucose simulation solution to verify whether the difference in the amount of enzyme on each microneedle is less than 10%. Finally, various experiments and analyses are carried out to reduce the size of the device, test effective durability (approximately 7 days), and the feasibility of minimally invasive CGMS is evaluated by tests on two persons. MDPI 2022-03-20 /pmc/articles/PMC8949222/ /pubmed/35334773 http://dx.doi.org/10.3390/mi13030478 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chien, Ming-Nan
Chen, Yu-Jen
Bai, Chin-Han
Huang, Jung-Tung
Continuous Glucose Monitoring System Based on Percutaneous Microneedle Array
title Continuous Glucose Monitoring System Based on Percutaneous Microneedle Array
title_full Continuous Glucose Monitoring System Based on Percutaneous Microneedle Array
title_fullStr Continuous Glucose Monitoring System Based on Percutaneous Microneedle Array
title_full_unstemmed Continuous Glucose Monitoring System Based on Percutaneous Microneedle Array
title_short Continuous Glucose Monitoring System Based on Percutaneous Microneedle Array
title_sort continuous glucose monitoring system based on percutaneous microneedle array
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949222/
https://www.ncbi.nlm.nih.gov/pubmed/35334773
http://dx.doi.org/10.3390/mi13030478
work_keys_str_mv AT chienmingnan continuousglucosemonitoringsystembasedonpercutaneousmicroneedlearray
AT chenyujen continuousglucosemonitoringsystembasedonpercutaneousmicroneedlearray
AT baichinhan continuousglucosemonitoringsystembasedonpercutaneousmicroneedlearray
AT huangjungtung continuousglucosemonitoringsystembasedonpercutaneousmicroneedlearray